Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care

pharmafile | August 15, 2018 | News story | Research and Development HIV, Janssen, ViiV Healthcare, pharma 

Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, for the treatment of HIV-1, demonstrating similar efficacy to a standard daily, oral three-drug regimen over a 48 week period, meeting its primary endpoint.

It was shown that HIV patients who had maintained viral suppression for at least six months, on a daily oral regimen comprised of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, maintained similar rates of viral suppression taking the combination of Janssen’s rilpivirine and ViiV’s cabotegravir compared to the standard regimen.

“These results offer new evidence that suggest this investigational, two-drug, once a month dosing regimen may reduce the impact of treatment on people’s lives,” said Dr Wim Parys, Head of R&D, Global Public Health at Janssen. “This novel approach would signify a much-needed treatment evolution for people living with HIV, moving from dosing 365 days a year to just 12 times per year.”

Full details of the findings of the trial will be presented at an upcoming scientific event. Janssen and ViiV’s regimen is currently not approved for use anywhere in the world.

Matt Fellows

Related Content

FDA relaxes blood donation regulations for MSM

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which …

GSK’s ViiV and Halozyme to collaborate on ‘ultra-long acting’ HIV drugs

ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline (GSK), is to collaborate with …

janssen_latest_logo_on_sign_closer

Janssen CLL treatment combination sees success in trials

Janssen has announced positive data from its Phase III GLOW study, with the combination of …

Latest content